



Transparency Declaration

-

Interactions with Members of the Public, Including Patients and Journalists in 2022 & 2023

Published June 2024

Chugai Pharma UK Ltd.

&

Chugai Pharma Europe Ltd.

Introduction

Chugai Pharma UK Ltd. and Chugai Pharma Europe Ltd. will occasionally work with members of the UK public, including patients and journalists and payments made will be disclosed via the company website. In these circumstances the individuals would be paid fees for certain contracted services, which may include speaking at meetings, assistance with training, writing articles and/or publications, participating in advisory boards, advising on the design etc of clinical trials and participating in market research where such participation involves remuneration and/or travel.

As per clause 24 of the 2021 ABPI Code of Practice, details will be given as to:

- The total number of members of the public, including patients and journalists contracted to perform services and the total amount paid per calendar year, and a description of the types of services provided that is sufficiently complete to enable the reader to understand the nature of the services provided without the necessity to divulge confidential information.
- A breakdown of the total payments to each group of individuals, i.e. the public, patients and journalists without the necessity to divulge confidential information.
- Fees and expenses will be disclosed separately.

[Interactions with Members of the Public in 2023](#)

[Interactions with Patients in 2023](#)

[Interactions with Journalists 2023](#)

[Interactions with Members of the Public in 2022](#)

[Interactions with Patients in 2022](#)

[Interactions with Journalists 2022](#)

The amounts indicated represents payments made in the UK and Ireland for each calendar year. The data has been sourced from all Chugai businesses in the UK. The amounts indicated excludes money spent by our partners where we co-promote products. The amounts shown are exclusive of VAT and taxes, where this is applicable.

Roche Products Limited and Chugai Pharma U.K. Ltd. have in place a co-promotion agreement for a Prescription Only Medicine (POM). To ensure both companies adhere with the ABPI requirements, each company will independently disclose payments associated with this co-promotion.

If you have any queries, please contact disclosure@chugai-pharm.co.uk

Interactions with Members of the Public in 2023

Chugai did not engage with any members of the public in 2023, therefore there are no interactions to disclose.

Interactions with Patients in 2023

Patients	Type	Amount	Description of types of services
	Travel Expenses	£216.00	N/A
	Fees	£1580.34	Speaker fees and service fees
Aggregate amount attributable to transfers of value to such Recipients - £1796.34			
Number of Recipients in aggregate disclosure - 14			

Interactions with Journalists 2023

Chugai did not engage with any journalists in 2023, therefore there are no interactions to disclose.

Interactions with Members of the Public in 2022

Chugai did not engage with any members of the public in 2022, therefore there are no interactions to disclose.

Interactions with Patients in 2022

Patients	Type	Amount	Description of types of services
	Travel Expenses	£403.70	N/A
	Fees	£490	Speaker fees and service fees
Aggregate amount attributable to transfers of value to such Recipients - £893.70			
Number of Recipients in aggregate disclosure - 102			

Interactions with Journalists 2022

Chugai did not engage with any journalists in 2022, therefore there are no interactions to disclose.